LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

Core Insights - LifeMD has announced a new lower cash-pay price for GLP-1 medications, Wegovy and Ozempic, at $199 per month for the 0.25 mg and 0.5 mg doses, which is the lowest cash-pay pricing available nationwide [1][4] - This pricing initiative is part of LifeMD's commitment to patient affordability and high-quality care, supporting patients who pay out of pocket [1][4] - The LifeMD Weight Management Program offers comprehensive support, including virtual consultations, diagnostic testing, secure messaging, and educational resources for sustained weight loss and metabolic health [2] Company Strategy - LifeMD's shift from compounded GLP-1s to direct partnerships with leading pharmaceutical manufacturers is central to its long-term growth strategy [4] - The company aims to maximize access to safe, FDA-approved medications through a frictionless virtual care experience [4] - LifeMD is well-positioned to deliver high-quality, affordable treatment options through a scalable, integrated virtual care platform, aligning with market needs and future healthcare trends [5] Market Context - The announcement follows national efforts to improve affordability and access to GLP-1 therapies, including initiatives from the White House and major pharmaceutical manufacturers like Novo Nordisk and Eli Lilly [3] - LifeMD's infrastructure and partnerships position it as a key player in supporting patients seeking clinically guided weight-loss care [3]